Grifols stock holds in single digits as Q2 2026 earnings miss consensus by a small margin
Published on 08/21/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols (ES0171996087) stock continues to trade in the single-digit range, with its Nasdaq-listed shares closing at $7.99 on August 20, 2026 after a prior close of $8.25, while the Madrid-listed shares last changed hands at 9.998 on August 20, 2026.
Recent price action and market context
On the US market, the American depositary shares of Grifols under the ticker GRFS ended the August 20, 2026 session at $7.99, down from a previous close of $8.25, implying a single-day decline of 3.15 percent.
In the home market, data as of August 20, 2026 show Grifols SA trading at 9.998 on the Madrid exchange, with an intraday range between 9.942 and 10.150 and a 52-week range from 8.432 to 12.870, placing the latest price closer to the lower end of that one-year corridor. Over the same 52-week span the stock has moved between those two extremes, and commentary from a US market portal notes that US-listed GRFS shares started 2026 at $9.35 and were recently quoted at $8.25, a decline of 11.8 percent year to date.
Half-year 2026 earnings and consensus comparison
For investors looking beyond day-to-day price moves, the key recent fundamental checkpoint is the second quarter of 2026. According to a detailed earnings overview, Grifols reported earnings per share of $0.21 for this period, modestly below the consensus forecast of $0.22. This one-cent gap underscores that the company largely met market expectations, but did not surpass them.
The same half-year 2026 report shows revenue for the quarter at $1.43 billion, highlighting the scale of Grifols plasma-derived medicines and diagnostics business. A related analysis indicates that the company generated a trailing twelve-month return on equity of 6.21 percent and maintained a net margin of 5.54 percent, suggesting that profitability, while positive, remains mid-single-digit as a percentage of sales.
An additional data point from a European quote overview notes that the earnings per share on a trailing-twelve-month basis stands at 0.660 in the home-market currency context, which, alongside the quarterly EPS figure, gives investors a sense of how much profit Grifols is generating per share across both short and longer horizons.
Valuation and performance signals
With US-listed GRFS shares having started 2026 at $9.35 and quoted at $8.25 in a recent snapshot, the implied year-to-date performance is a decline of 11.8 percent. That underperformance versus the starting point reflects investor caution, even as the company continues to post positive earnings.
The combination of a 52-week range between 8.432 and 12.870 on the Madrid market and a current price of 9.998 places Grifols closer to its recent lows than its highs, which investors may interpret as the stock trading at a discount relative to levels seen over the prior year. At the same time, a 5.54 percent net margin and 6.21 percent return on equity suggest that the business is generating profits, though not yet at the higher-margin levels sometimes seen in other large health care companies.
From a risk perspective, the small miss versus the $0.22 earnings-per-share consensus in the second quarter of 2026 indicates that Grifols has stayed relatively close to analyst expectations. The revenue figure of $1.43 billion for that quarter, when viewed alongside trailing earnings, can help investors consider whether the current single-digit share price reflects a fair multiple of recent profits or embeds a discount linked to past balance sheet concerns.
Plasma-derived therapies underpin the business
Grifols core business revolves around collecting human plasma and manufacturing plasma-derived therapies used to treat conditions such as immunodeficiencies and bleeding disorders. The company operates a network of plasma donation centers and runs large-scale fractionation facilities that separate plasma into key proteins like immunoglobulins, albumin and clotting factors.
In addition to plasma medicines, Grifols has a diagnostics division that provides testing instruments and reagents for blood and plasma screening, supporting both its own collection network and external blood banks. This mix of therapeutic and diagnostic activities creates multiple revenue streams tied to the global demand for safe blood and plasma products.
Current trading snapshot for Grifols stock
As of the most recent completed US trading session on August 20, 2026, Grifols American depositary shares closed at $7.99 on the Nasdaq market, reflecting the price level at 4:00 p.m. ET for that day. On the same date in Spain, the Madrid-listed shares finished at 9.998, with intraday fluctuations between 9.942 and 10.150 and a recorded 52-week band from 8.432 to 12.870.
Read more on Grifols
Further details on the companys strategy, financing and recent financial performance are available on its investor-facing website, which provides access to half-year and annual reports, presentations and other regulatory filings for shareholders and analysts.
Fact box
Company: Grifols, S.A.
ISIN: ES0171996087
Ticker: GRFS
Exchange: Nasdaq (ADR), Madrid (home listing)
Price (as of August 20, 2026, 4:00 p.m. ET): $7.99 USD for the ADR, 9.998 in the home-market listing
52-week range (home market): 8.432 to 12.870
Trailing EPS: 0.660 (home-market measure)
Q2 2026 EPS: $0.21 versus $0.22 consensus
Q2 2026 revenue: $1.43 billion
